By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Alcon Pharmaceuticals, Ltd. et al. v. Apotex Inc. et al.
4:11-cv-00600; filed August 25, 2011 in the Northern District of Texas
• Plaintiffs: Alcon Pharmaceuticals, Ltd.; Alcon Research, Ltd.
• Defendants: Apotex Inc.; Apotex Corp.
Infringement of U.S. Patent No. 7,977,376 ("Olopatadine Formulations for Topical Nasal Administration," issued July 12, 2011) following a Paragraph IV certification as part of Apotex's filing of an ANDA to manufacture a generic version of Alcon's Patanase® (olopatadine hydrochloride, used to treat seasonal allergic rhinitis). View the complaint here.
Cadence Pharmaceuticals, Inc. et al. v. Exela Pharma Sciences, LLC et al.
5:11-cv-00116; filed August 24, 2011 in the Western District of North Carolina
• Plaintiffs: Cadence Pharmaceuticals, Inc.; SCR Pharmatop
• Defendants: Exela Pharma Sciences, LLC; Exela Pharmsci, Inc.; Exela Holdings, Inc.
Cadence Pharmaceuticals, Inc. et al. v. Paddock Laboratories, Inc. et al.
1:11-cv-00880; filed August 19, 2011 in the Western District of Michigan
• Plaintiffs: Cadence Pharmaceuticals, Inc.; SCR Pharmatop
• Defendants: Paddock Laboratories, Inc.; Perrigo Co.; Paddock Laboratories, LLC
Cadence Pharmaceuticals, Inc. et al. v. Paddock Laboratories, Inc. et al.
0:11-cv-02399; filed August 19, 2011 in the District Court of Minnesota
• Plaintiffs: Cadence Pharmaceuticals, Inc.; SCR Pharmatop
• Defendants: Paddock Laboratories, Inc.; Perrigo Co.; Paddock Laboratories, LLC
Cadence Pharmaceuticals Inc. et al.. v. Paddock Laboratories et al.
1:11-cv-00733; filed August 18, 2011 in the District Court of Delaware
• Plaintiffs: Cadence Pharmaceuticals Inc.; SCR Pharmatop
• Defendants: Paddock Laboratories Inc.; Perrigo Co.; Paddock Laboratories LLC; Exela Pharma Sciences LLC; Exela Pharmsci Inc.; Exela Holdings Inc.
The complaints in these cases are substantially identical. Infringement of U.S. Patent Nos. 6,028,222 ("Stable Liquid Paracetamol Compositions, and Method for Preparing the Same," issued February 22, 2000) and 6,992,218 ("Method for Obtaining Aqueous Formulations of Oxidation-Sensitive Active Principles," issued January 31, 2006), both licensed to Cadence, following a Paragraph IV certification as part of defendants' filing of an ANDA to manufacture a generic version of Cadence's Ofirmev® (acetaminophen injection, used for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fevers). View the Paddock (Delaware) complaint here.
Comments